Model for end-stage liver disease (MELD) exception for cystic fibrosis

被引：13
|
作者：
Horslen, Simon
Sweet, Stuart
Gish, Robert G.
Shepherd, Ross
机构：
[1] Calif Pacific Med Ctr, Dept Med, San Francisco, CA 94115 USA
[2] Calif Pacific Med Ctr, Dept Transplantat, San Francisco, CA 94115 USA
[3] Calif Pacific Med Ctr, Div Hepatol & Complex GI, Phys Fdn, San Francisco, CA 94115 USA
[4] Childrens Hosp, Seattle, WA USA
[5] Reg Med Ctr, Seattle, WA USA
[6] Washington Univ, St Louis Childrens Hosp, Sch Med, St Louis, MO 63110 USA
[7] Washington Univ, Sch Med, St Louis, MO USA
来源：
LIVER TRANSPLANTATION | 2006年 / 12卷 / 12期
关键词：
D O I：
10.1002/lt.20967
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [21] Graphical display of Model for End-stage Liver Disease (MELD) score
    Chiarla, Carlo
    Giovannini, Ivo
    Ardito, Francesco
    Vellone, Maria
    Giuliante, Felice
    [J]. LIVER INTERNATIONAL, 2012, 32 (08) : 1322 - 1323
  • [22] Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Bruno, Raffaele
    Sacchi, Paolo
    Filice, Gaetano
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 123 - 123
  • [23] Impact of model for end-stage liver disease (MELD) and delta MELD (MELD) on outcome following liver transplantation.
    Bhati, CS
    Tamijmarane, A
    Gunson, B
    Mayer, DF
    Buckels, JAC
    Mirza, DF
    Wigmore, SJ
    Brahmall, SR
    [J]. LIVER TRANSPLANTATION, 2006, 12 (05) : C80 - C80
  • [24] THE IMPACT OF LISTING MODEL FOR END-STAGE LIVER DISEASE (MELD) SCORE ON LIVER TRANSPLANTATION
    Fox, Alyson N.
    Reddy, Rajender
    Guttenberg, Katie B.
    Forde, Kimberly A.
    Ellenberg, Susan
    Lewis, James D.
    [J]. HEPATOLOGY, 2010, 52 (04) : 664A - 664A
  • [25] Impact of the Model for End-Stage Liver Disease (MELD) Score on Liver Transplantation in Greece
    Karapanagiotou, A.
    Kydona, C.
    Dimitriadis, C.
    Papadopoulos, S.
    Theodoridou, T.
    Tholioti, T.
    Fouzas, G.
    Imvrios, G.
    Gritsi-Gerogianni, N.
    [J]. TRANSPLANTATION PROCEEDINGS, 2014, 46 (09) : 3212 - 3215
  • [26] MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
    Kim, W. Ray
    Mannalithara, Ajitha
    Heimbach, Julie K.
    Kamath, Patrick S.
    Asrani, Sumeet K.
    Biggins, Scott W.
    Wood, Nicholas L.
    Gentry, Sommer E.
    Kwong, Allison J.
    [J]. GASTROENTEROLOGY, 2021, 161 (06) : 1887 - +
  • [27] Improvements in the model for end-stage liver disease (MELD) severity score.
    Dykstra, DM
    Wiesner, RH
    Port, FK
    Wolfe, RA
    Merion, RM
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 516 - 516
  • [28] Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
    Lau, Tsang
    Ahmad, Jawad
    [J]. HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2013, 5 : 1 - 10
  • [29] Mayo end-stage liver disease (MELD) score: Causes of variability in patients with end-stage liver disease (ESLD)
    Yousfi, MM
    Douglas, DD
    Malinchoc, M
    Mulligan, DC
    Rakela, J
    Moss, AA
    Harrison, ME
    Balan, V
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A371 - A371
  • [30] Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception
    DuBrock, Hilary M.
    del Valle, Kathryn T.
    Krowka, Michael J.
    [J]. LIVER TRANSPLANTATION, 2022, 28 (07) : 1224 - 1230
12345